STOCKER1970 / SHUTTERSTOCK.COM
This year’s Life Sciences Law Forum is taking place on June 25 in London. LSIPR caught up with the conference’s chair James Horgan, of Merck Sharp & Dohme, and GlaxoSmithKline counsel Anthony Kenny to find out what’s keeping them busy and what they’ll discuss on the day.
James Horgan, legal director of European patents at Merck Sharp & Dohme (MSD)
What is your day-to-day role at MSD, and what projects are you working on at the moment?
The team of patent attorneys here is responsible for prosecuting the vast majority of MSD’s patent applications in Europe, and that includes defending oppositions against our own patents and filing oppositions against third parties. We also file large numbers of supplementary protection certificates (SPCs), and there will be a lot of those in a year when there are a number of new product launches.
On top of this, we get involved in some of MSD’s patent litigation in the UK and Europe, as well as supporting business needs with due diligence and general patent questions.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
MSD, Merck Sharp & Dohme, SPCs, patent, patent application, Life Sciences Law Forum